- Home
- NAVI vs PHAR Comparison
NAVI vs PHAR Comparison
Compare NAVI & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAVI | PHAR |
|---|---|---|
| Founded | 1973 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NAVI | PHAR |
|---|---|---|
| Price | $12.94 | $17.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $13.83 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 970.8K | 24.5K |
| Earning Date | 01-28-2026 | 11-06-2025 |
| Dividend Yield | ★ 4.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.00 |
| Revenue | ★ $443,000,000.00 | $362,274,000.00 |
| Revenue This Year | N/A | $25.19 |
| Revenue Next Year | N/A | $4.47 |
| P/E Ratio | ★ N/A | $3,041.40 |
| Revenue Growth | N/A | ★ 26.78 |
| 52 Week Low | $10.53 | $7.50 |
| 52 Week High | $16.07 | $18.30 |
Technical Indicators
Market Signals| Indicator | NAVI | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 55.57 | 58.10 |
| Support Level | $12.89 | $16.98 |
| Resistance Level | $13.21 | $17.00 |
| Average True Range (ATR) | 0.32 | 0.69 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 59.57 | 82.04 |
Price Performance
Historical ComparisonAbout NAVI Navient Corporation
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in three segments: Federal Education Loans, Consumer Lending, and Business Processing. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.